Anthem Biosciences IPO Details
MAINBOARD
Anthem Biosciences IPO opens for subscription on 14 Jul 2025 and closes on 16 Jul 2025. The IPO will be listed on NSE, BSE with the tentative listing date set for 21 Jul 2025.
Anthem Biosciences IPO price band has been fixed at ₹540 – ₹570 per share.The face value is ₹2 per share with a lot size of 26.
Anthem Biosciences IPO total issue size comprises 5,95,61,404 shares (aggregating up to ₹3,395.00 Cr). Offer for Sale consists of 5,95,61,404 shares (aggregating up to ₹3395.00 Cr). Pre-issue shareholding stands at 55,90,77,100, which will increase to 55,90,77,100 post-issue.
Anthem Biosciences IPO carries a ₹179 (31.4%) GMP, reflecting investor sentiment.
Anthem Biosciences IPO Lot Size : Retail Minimum is 1 lot (26 shares) amounting to ₹14,820. Retail Maximum is 13 lots (338 shares) amounting to ₹192,660. SHNI Minimum is 14 lots (364 shares) amounting to ₹207,480. SHNI Maximum is 67 lots (1,742 shares) amounting to ₹992,940. BHNI Minimum is 68 lots (1,768 shares) amounting to ₹1,007,760.
The Lead Managers for Anthem Biosciences IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is JP Morgan India Pvt Ltd, Jm Financial Ltd, Citigroup Global Markets India Pvt Ltd, Nomura Financial Advisory & Securities (India) Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Anthem Biosciences Limited RHP.
Anthem Biosciences IPO Details
Anthem Biosciences IPO Subscription
Anthem Biosciences IPO Application Wise Breakup (Approx)
Anthem Biosciences IPO Dates
- 14 Jul 2025Opening dateOpen
- 16 Jul 2025Closing dateClose
- 17 Jul 2025Allotment Date Allotment
- 18 Jul 2025Initiation of RefundsRefund
- 18 Jul 2025Credit of SharesCredit
- 21 Jul 2025Listing dateListing
Anthem Biosciences IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 26 | ₹14,820 |
| Retail Maximum | 13 | 338 | ₹192,660 |
| SHNI Minimum | 14 | 364 | ₹207,480 |
| SHNI Maximum | 67 | 1742 | ₹992,940 |
| BHNI Minimum | 68 | 1768 | ₹1,007,760 |
Anthem Biosciences IPO Reservation
Promoter Holding
Anthem Biosciences IPO Valuations
Anthem Biosciences Financial Information
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 2,692.51 | 2,398.11 | 2,014.46 | 1,618.87 |
| Revenue | 910.85 | 1,483.07 | 1,133.99 | 1,280.24 |
| Profit After Tax | 244.31 | 367.31 | 385.19 | 405.54 |
| EBITDA | 327.50 | 519.96 | 446.05 | 587.31 |
| Net Worth | 2,204.37 | 1,924.66 | 1,740.67 | 1,355.00 |
| Reserves and Surplus | 2,095.49 | 1,815.39 | 1,628.88 | 1,347.64 |
| Total Borrowing | 131.26 | 232.53 | 125.06 | 35.49 |
| Amount in ₹ Crore | ||||
About Anthem Biosciences IPO
Incorporated in 2006, Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (“CRDMO”) with fully integrated operations encompassing drug discovery, development, and manufacturing processes.
The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale.
The company manufactures specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
For the six months concluding on September 30, 2024, the company engaged in the manufacture of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been supported since their discovery.
As of September 30 2024, the company had 196 projects: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).
As of September 30 and March 31, 2024, the company had over 425 and 550 customers in our CRDMO and specialty ingredients businesses, spanning more than 44 countries, including the U.S., Europe, and Japan.
As of March 31, 2024, the company served over 150 customers, from small biotech to large pharmaceutical companies.
As of September 30, 2024, the company holds one patent in India, seven overseas, and has 24 pending global patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.
As of September 30 2024, the company's team consists of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, experts in various in-vivo non-clinical research and chemical engineers.
Strength Of Anthem Biosciences IPO
- Comprehensive services across the drug life cycle for small molecules and biologics
- Focus on advanced solutions across modalities and manufacturing practices
- Specialised model for small pharmaceutical and biotech companies
- Established customer base with ongoing relationships
- Experienced leadership and skilled scientific team
Risk Of Anthem Biosciences IPO
- Failure to develop new or improve existing technologies.
- Delays in obtaining regulatory approvals.
- Under-utilisation of manufacturing capacity and demand forecasting issues.
- Pricing pressures affecting product prices and profitability.
- Risks from data security breaches and failure to safeguard sensitive information.
- Seasonality affecting business performance and cash flow.
Objectives Anthem Biosciences IPO
To be announced
Company Contact Details
Anthem Biosciences Limited
No. 49, F1 & F2, Canara Bank Road
Bommasandra Industrial Area, Phase 1,
Bommasandra,
Bengaluru, Karnataka, 560099
Phone: +91 080 6672 400
Email: investors.abl@anthembio.com
Website: https://www.anthembio.com/
Registrar Contact Details
Anthem Biosciences IPO - FAQs
The Anthem Biosciences IPO is a MAINBOARD public issue comprising 59561404 equity shares with a face value of ₹2 each, aggregating to a total issue size of ₹3,395.00 Cr. The issue price has been fixed at ₹570 per equity share, and the minimum application size is 26 shares.
The IPO opens for subscription on 14 Jul 2025, and closes on 16 Jul 2025.
Kfin Technologies Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at ₹179 (31.4%).